ERBB2 and breast carcinoma: Two-hundred twenty-four HR+ and HER2- breast cancer patients were included in the study (Table 1) with 202 (90.2%) of the patients diagnosed with no metastasis during the development of their breast cancer and 185 (82.6%) treated with adjuvant chemotherapy.